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Caspase-8Abstract Hepatocellular carcinomas will emerge as a major form of malignancy in the coming dec-
ades. When these tumors are in advanced stages, few therapeutic options are available. Therefore, it
is essential to search for new treatment modalities to ﬁght this disease.
Aim: Evaluate the possible protective and therapeutic effects of Cannabis extract on dimethylnitro-
samine (DMNA)-induced hepatocarcinogenicity in mice.
Methods: Seventy-ﬁve male mice were divided into ﬁve groups of 15 each: group I mice received
corn oil only as the control group; group II mice were injected intraperitoneally with DMNA
(10 lg/kg body weight) weekly for 12 weeks; group III mice were pretreated orally with cannabis
extract (0.5 ml/kg body weight) every other day for two weeks before the injection of DMNA,
and continued until the end of the experiment (12 weeks); group IV mice were treated orally with
cannabis extract every other day simultaneously with DMNA injection and continued until the
end of the experiment; group V mice were treated orally with cannabis extract every other day after
receiving the last intraperitoneal injection of DMNA. A real time PCR was used to quantify
telomerase reverse transcriptase and caspase-8 m-RNA expression level.CND,
Hadra
ail.com
oo.com
242 N.A.E.M. Hussein et al.Results: As compared to the control group, mTERT mRNA expression level was signiﬁcantly
increased in group II. The gene in groups (III, IV, and V) was insigniﬁcantly higher than the control
group but it was signiﬁcantly decreased as compared to group II. The caspase-8 mRNA expression
level was signiﬁcantly decreased in all groups as compared to the control group. As compared to
group II, caspase-8 mRNA level was signiﬁcantly increased in group III.
Conclusion: The protective effect of cannabis extract is more pronounced in group taking cannabis
before DMNA. Cannabinoids might exert their anti-tumor effects by the direct induction of apop-
tosis and can decrease telomerase activity by inhibiting the expression of the TERT gene. Coordi-
nation between inhibition of telomerase activity and induction of apoptosis might be a potential
therapeutic agent for cancer treatment.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
solid tumors and the third leading cause of cancer-related
death worldwide.1 Its prognosis remains reserved, with a
5-year survival rate of <5%.2 Hepatocarcinogenesis is a
multi-step process involving different genetic alterations that
ultimately lead to malignant transformation of the hepato-
cytes.3,4 One of the molecular events that underlie the multige-
netic process of hepatocarcinogenesis is the activation of
human telomerase reverse transcriptase (hTERT) which is nor-
mally suppressed in most human somatic tissues after birth.5,6
The replicative potential of eukaryotic cells is regulated
through specialized DNA structures called telomeres, which
cap the ends of the chromosomes. Telomerase is a ribonu-
cleoprotein complex composed of two essential components:
a catalytic subunit with reverse transcriptase activity
(hTERT) and RNA subunit with human telomerase RNA
(hTR). In the adult organism, telomerase expression is
restricted to a few cell types, most notably germ cells and
stem/progenitor cells. Telomerase has been a target of
increasing interest because high telomerase activity is one of
the mechanisms that sustain the unlimited growth of cancer
cells.7,8 The hTERT gene encodes the catalytic subunit of tel-
omerase, which mediates pleiotropic effects, including the
regulation of senescence and proliferation and plays an
important role in carcinogenesis.9
Programed cell death (apoptosis) is a potent mechanism
that limits the expansion of tumor cells by triggering their sui-
cide, while defects in apoptosis underpin both tumorigenesis
and metastasis.10 Caspase-8 belongs to the caspase family of
proteases and plays a key role in the regulation of apoptosis
during normal development as well as in adult life. Since sig-
naling via the death receptor (extrinsic) pathway critically
depends on caspase-8, the distribution of caspase-8 expression
or function may contribute to human diseases.11
Cannabis (bhang, ganja, charas, hashish, kif, marijuana
etc.) is one of the popular plants among common people since
time immemorial due to its various uses and abuses. The hemp
plant Cannabis sativa produces unique compounds known as
cannabinoids (CND).12 The most important cannabinoids
found in the cannabis plant are tetrahydrocannabinol
(D9THC) and cannabidiol (CBD). Cannabinoids have been
shown to be effective in the treatment of nausea and vomitingassociated with cancer chemotherapy, anorexia and cachexia
seen in HIV/AIDS patients, as well as neuropathic pain, and
spasticity in multiple sclerosis.13,14
Therefore, the aim of the present study was to evaluate the
possible protective and therapeutic effects of Cannabis extract
on dimethylnitrosamine-induced hepato-carcinogenicity in
mice through studying TERT m-RNA, caspase-8 m-RNA
gene expression levels, alanine transaminase (ALT), aspartate
transaminase (AST) and gamma-glutamyl transpeptidase (c-
GT) activities.2. Materials and methods
2.1. Preparation of plant extract
Cannabis sativa plant (the ﬂowering tops of plants) was
obtained by permission from the Public Prosecutor. One hun-
dred gms of dry cannabis plant were minced into very small
pieces and boiled with water for 5 min. The boiling water
was discarded and the minced plant was left to dry at room
temperature. Extraction was carried out by boiling the dried
minced plant with 100 ml of ethyl alcohol for 10 min followed
by ﬁltration. The ﬁltrate was transported into a speciﬁc appa-
ratus used to evaporate cannabis residue by heating at speciﬁc
temperatures (180–220 C) to obtain cannabinoids free of
some carcinogenic compounds (such as benzopyrene, benzene,
toluene and naphthalene). The residue was heated up to
180 C, the vapor was collected in petroleum ether (for trap-
ping hydrocarbons) and then discarded. On raising the temper-
ature from 180 C to 220 C the resulting vapor (contains
cannabinoids) was received in methyl alcohol (trapping
agent).15
Mass spectroscopy coupled with gas chromatography (GC/
MS)16 was used as a method for detection of the received can-
nabinoids using column hp 5, capillary 30 m, GC type is Agi-
lent 6890N, mass is Agilent 5973 N. Temperature program:
start of 50 C for 3 min, then temperature was increased
at a rate of 50 C/min up to 280 C for 25 min. Injection tem-
perature = 250 C, detector temperature = 280 C, injection
volume = 3 ll and wavelength k= 50–550 M/Z (M=molec-
ular weight, Z = charge). Methyl alcohol was evaporated and
the cannabinoids’ residue was dissolved in 100 ml of corn oil
until time of use.
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The experiments were conducted on seventy-ﬁve male mice
weighing 20 ± 2 g and were housed in plastic cages at room
temperature of 22 ± 1 C under a 12 h light-dark cycle. The
studies were carried out in accordance with the current ethical
guidelines for investigation approved by the Ethics Committee
of Medical Research Institute.
Animals were divided into ﬁve groups of 15 each. The
groups were as follows: group I mice received corn oil only
and served as the control group; group II mice were injected
intraperitoneally with dimethylnitrosamine (DMNA 10 lg/kg
body weight) weekly for 12 weeks;17 group III mice were pre-
treated orally with cannabis extract (0.5 ml/kg body weight)18
every other day for two weeks before the intraperitoneal injec-
tion of DMNA, and continued until the end of the experiment
(12 weeks); group IV mice were treated orally with cannabis
extract (0.5 ml/kg body weight) every other day simultaneously
with an intraperitoneal injection of DMNA and continued
until the end of the experiment (12 weeks); group V mice were
treated orally with cannabis extract (0.5 ml/kg body weight)
every other day after receiving the last intraperitoneal injection
of DMNA (12 weeks).
At the end of experiment, the mice were fasted overnight
and then sacriﬁced under light ether anesthesia and the liver
was divided into three parts:
- First part was used for total RNA extraction.
- Second part was used for liver tissue homogenate
preparation.
- Third part was ﬁxed in 10% formalin for histopathological
examination.2.3. Relative quantiﬁcation of TERT mRNA and caspase-8
mRNA gene by real time PCR using SYBR green.19,20
2.3.1. RNA extraction
Total RNA was extracted using Gene JET RNA Puriﬁcation
Kit (Fermentas) following the manufacturer’s instructions
and the standard protocol. RNA was detected by electropho-
resis using a 1.0% agarose gel containing ethidium
bromide (0.5 lg/ml) for 40 min at 100 V and the gel was
observed under UV light. The eluted RNA was collected
immediately, placed in ice or stored at 20 C for further
processing.2.3.2. cDNA preparation
cDNAs were synthesized from the mRNA by high capacity
cDNA reverse transcription kit (Applied Biosystems, Foster
City, CA, USA) using a PCR thermocycler (Applied Biosys-
tem). cDNA prepared for real time PCR was stored at 15
to 25 C.2.3.3. Real time PCR
For each sample, 5 ll cDNA was used for RT-PCR using the
Power SYBR Green RT-PCR Master Mix kit (Applied Bio-
systems, Foster City, CA, USA) and the real time machine(Applied Biosystems one step, Foster City, CA, USA) to detect
relative expression levels of mTERT mRNA19 and caspase-8
mRNA.20 The reaction conditions used to detect TERT and
caspase-8 levels were: initial DNA denaturation at 95 C for
10 min and then 40 cycles of denaturation at 95 C for 15 s,
annealing and elongation at 60 C for 1 min. GAPDH (glycer-
aldehyde 3-phosphate dehydrogenase; housekeeping gene was
used as an endogenous control) was included in each
experiment.
2.3.4. Primers sequence
(Sigma-Aldrich Co., St. Louis, MO, USA) mTERT was (50-
ATGGCGTTCCTGAGTATGGGTGC-30) mTERT-forward
and (50-ACTTCAACCGCAAGACCGACAGG-30) mTERT-
reverse.21
Caspase-8 was (50-TCGCCCGAGCTGGAGTTGTGA-30)
caspase-8-forward and (50-CTCGGTTGCAGTCTAGGAA-
GTTGA-30) Caspase-8-reverse.20
GAPDH was (50-ACCACAGTCCATGCCATCAC-30)
GAPDH-forward and (50-TCCACCACCCTGTTGCTGTA-
30) GAPDH-reverse.21
The amount of target, normalized to an endogenous refer-
ence and relative to a calibrator, is given by 2DDCT where
CT = Threshold cycle. DCT= CTt  CTr where DCT= the
difference in threshold cycles for target and reference.
DDCT ¼ DCTcases  DCTcalibrators2.4. Biochemical analysis of hepatic liver enzymes
The liver was immediately removed, weighed, washed
using chilled saline solution and homogenized (10% w/v) in
0.01 M sodium phosphate buffer (pH 7.4) in a Potter-elvehjem
type homogenizer. The homogenate was centrifuged at
10,000 · g for 20 min at 4 C, and the resultant supernatant
was used for ALT, AST and c-GT levels determination
using a kit (spectrum, Germany), according to the manufac-
turer’s instructions. Enzyme activities were expressed in terms
of U/L.2.5. Histopathological examination
Liver tissues were ﬁxed in 10% formalin, sectioned, and
stained with hematoxylin and eosin (H and E).2.6. Statistical analysis
Data were fed to the computer using IBM SPSS software pack-
age version 20.0. Quantitative data were described using mean
and standard deviation. For normally distributed data, com-
parisons between different groups were analyzed using F-test
(ANOVA) and Post Hoc test (Scheffe) for pair wise compari-
son. Signiﬁcance test results are quoted as two-tailed probabil-
ities. Signiﬁcance of the obtained results was judged at the 5%
level. A difference was considered signiﬁcant at p 6 0.05.
Spearman’s correlation coefﬁcient was used to measure the
closeness of a linear relationship between all parameters in
all studied groups.
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3.1. Chromatography results
In Fig. 1, the GC chromatogram showed that the retention
times of cannabis vapor extract constituents are 7.03 and
7.44 min, identical to the retention times of D9THC andFigure 2 GC/MS chromatograms showing that the cannabi
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Figure 1 GC chromatogramCBD standards, respectively. The relative amounts are
67.9% for D9THC and 32.1% for CBD. The phenotype
ratio of cannabis extract = THC%/CBD%= 67.9%/
32.1%> 1.
GC/MS allows positive identiﬁcation of D9THC and CBD
in cannabis vapor extract which is shown in Fig. 2(A and B)
with base peaks at 231 for each constituent.s vapor extract contains (A) D9THC and (B) cannabidiol.
6.9 7.2 7.5 7.8
7.03
7.44
of cannabis vapor extract.
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The ampliﬁcation plots of ﬂuorescence intensity against the
PCR cycle from tissue samples and melting curves of both
TERT mRNA and caspase-8 mRNA are shown in Figs. 3
and 4 respectively.
The mTERT expression level was signiﬁcantly increased in
group II as compared to the control group (p1 < 0.001). The
gene level in groups (III, IV, and V) was insigniﬁcantly higher
than the control group (p1 = 1.000, 1.000, and 0.952 respec-
tively) but it was signiﬁcantly decreased as compared to group
II (p2 < 0.001). The mTERT expression in groups (IV, V) did
not show any signiﬁcant difference when compared with group
III (p3 = 1.000, 0.971 respectively) or with each other
(p4 = 0.981) (Table 1).
The caspase-8 expression level was signiﬁcantly decreased
in all groups as compared to the control group (p1 < 0.001).
As compared to group II, caspase-8 expression level was signif-
icantly increased in group III (p2 = 0.031), while in groups IV
and V it did not show any signiﬁcant difference (p2 = 0.992,
1.000 respectively). As compared to group III, caspase-8
expression level in group IV did not show any signiﬁcant dif-
ference (p3 = 0.098), while in group V it was signiﬁcantly
decreased (p3 = 0.038). Group V did not show any signiﬁcant
difference when compared with group IV (p4 = 0.996)
(Table 1).
ALT and AST activities were signiﬁcantly decreased in all
groups as compared to the control group (p1 < 0.001) and sig-
niﬁcantly increased in groups (III, IV and V) as compared to
group II (p2 < 0.001). As compared to group III, ALT activity
was signiﬁcantly decreased in group IV (p3 = 0.001), while in
group V it did not show any signiﬁcant difference (p3 =
0.998). In group V, the ALT activity was signiﬁcantly higher
than in group IV (p4 = 0.002). AST activity in groups (IV
and V) did not show any signiﬁcant difference when comparedFigure 3 (A) Ampliﬁcation plot and (B) melting curves of TERT m-R
is group III, D is group IV and E is group V.with group I (p3 = 0.131, 0.752 respectively) or with each
other (p4 = 0.752) (Table 1).
The c-GT activity was signiﬁcantly increased in all groups
as compared to the control group (p1 < 0.001) while it was sig-
niﬁcantly decreased in groups (III, IV and V) as compared to
group II (p2 < 0.001). As compared to group III, c-GT activ-
ity was signiﬁcantly increased in group IV (p3 = 0.008), while
in group V it did not show any signiﬁcant difference (p3 =
0.721). c-GT activity was signiﬁcantly decreased in group V
as compared to group IV (p4 = 0.013) (Table 1).
There was a signiﬁcant positive correlation between ALT,
AST (r= 0.951, p 6 0.001) and caspase-8 gene expression
and also between c-GT activity and TERT gene expression.
The signiﬁcant negative correlation between c-GT and each
of ALT (r= 0.886, p< 0.001), AST activities (r= 0.883,
p< 0.001), and caspase-8 gene expression was observed and
also between TERT gene expression and the activities of both
ALT and AST (Fig. 5A and B).
3.3. Histopathological results
Group I: showed normal hepatic architecture with no evidence
of inﬂammation, ﬁbrosis, necrosis, neoplasia or dysplasia
(Fig. 6).
Group II: Receiving DMNA: All hepatic sections showed
well to moderately differentiated HCC. Trabeculae several
cells thick are seen lined by pleomorphic hepatocytes with
hyperchromatic nuclei and abnormal mitotic ﬁgures. The
stroma was scantly formed of sinusoidal vessels. Necrosis
when present was always focal and there was no ﬁbrosis
(Fig. 7).
Group III: Cannabis before DMNA: All cases developed
well to moderately differentiated HCC. Signs of tumor regres-
sion were present in the form of frequent apoptotic hepato-
cytes with condensed pyknotic nuclei surrounded byNA for all the studied groups, where A is group I, B is group II, C
Figure 4 (A) Ampliﬁcation plot and (B) melting curves of caspase-8 m-RNA for all studied groups.
246 N.A.E.M. Hussein et al.perinuclear halo. Wide areas of necrosis were seen with sec-
ondary inﬁltration by acute and chronic non-speciﬁc inﬂam-
matory cells (Fig. 8).
Group IV: Cannabis plus DMNA: All cases developed
HCC of well differentiated morphology. Coagulative necrosisand scattered apoptotic hepatocytes and bodies characterized
this group (Fig. 9).
Group V: Cannabis after DMNA: All cases showed well
to moderately differentiated HCC. The majority of cases
showed viable tumor with occasional spotty foci of coagulative
Table 1 Hepatic TERT mRNA, caspase-8 m-RNA expression level (copies), ALT, AST and c-GT activities (U/L) for all studied
groups.
Groups TERT mRNA
expression level (copies)
Caspase-8 mRNA
expression level (copies)
ALT activity
(U/L)
AST activity
(U/L)
c-GT activity
(U/L)
Control (gp I)
1.22 ± 0.62 1.08 ± 0.41 345.47 ± 13.06 434.8 ± 23.58 5.02 ± 0.12
DMNA (gp II)
116.13 ± 61.47a 0.11 ± 0.04a 139.87 ± 8.20a 205.0 ± 12.49a 8.21 ± 0.49a
Cannabis before DMNA (gp III)
2.29 ± 1.52b 0.35 ± 0.12a,b 285.93 ± 11.93a,b 362.33 ± 19.88a,b 6.54 ± 0.24a,b
Cannabis plus DMNA (gp IV)
3.08 ± 4.25b 0.15 ± 0.09a 265.93 ± 11.93a,b,c 342.33 ± 19.88a,b 7.12 ± 0.31a,b,c
Cannabis after DMNA (gp V)
9.60 ± 7.0b 0.12 ± 0.04a,c 284.40 ± 13.30a,b,d 352.53 ± 23.22a,b 6.70 ± 0.26a,b,d
Statistically signiﬁcant at p 6 0.05.
ANOVA test used for comparing between the different studied groups.
Number for each group (n) = 15.
a Comparing with control group (I).
b Comparing groups III, IV, V with group II.
c Comparing groups IV, V with group III.
d Comparing group V with group IV.
r = -0.78; p < 0.001
r = -0.79; p < 0.001
r =  0.60; p < 0.001
r =  0.60; p < 0.001
r =  0.60; p < 0.001
r = -0.76; p < 0.001
A B
Figure 5 Correlation between (A) mTERT and (B) caspase-8 mRNA foreach ALT, AST and GGT.
Effects of cannabis plant extract on liver cancer 247necrosis and moderate number of apoptotic cells and bodies
(Fig. 10).
4. Discussion
The most important mechanism of liver cancer progression is
cell proliferation. Although in recent years several clinical tri-
als have tested the efﬁcacy of agents that selectively target
important signaling pathways involved in the control of this
process, no relevant improvement in the prognostic/survival
of patients with HCC has been achieved so far, and, therefore,
it is necessary to identify novel therapeutic strategies for the
management of HCC.22Cannabis vaporization is a relatively new technology aimed
at suppressing respiratory toxins (e.g. benzopyrene, naphtha-
lene, benzene and toluene) by heating cannabis to tempera-
tures below the point of combustion when smoke and
associated toxins are produced (near 230 C). The electric
vaporizer can successfully generate THC at 185 C while com-
pletely suppressing toxins.23,24
The results obtained from the chromatograms indicate that
the cannabis vapor extract consists of 67.9% of D9THC and
32.1% of CBD free from hazardous compounds. The pheno-
type ratio of cannabis plant, where cannabis preparation with
ratio greater than 1.0, is classiﬁed as the drug phenotype or
biologically active or more precisely as D9THC phenotype.
Figure 6 (Control group) showing normal hepatic architecture
(H&E ·400).
Figure 7 (Group II) showing well differentiated HCC with foci
of necrosis (H&E ·400).
Figure 8 (Group III) moderately differentiated HCC showing
frequent apoptotic ﬁgures (H&E, ·400).
Figure 9 (Group IV) HCC showing necrosis (center) and
apoptotic bodies (arrows) (H&E, ·400).
Figure 10 (Group V) HCC showing frequent apoptotic bodies
(fragmented chromatin) (H&Estain, ·400).
248 N.A.E.M. Hussein et al.However, that is with a ratio smaller than 1.0 classiﬁed as ﬁber
phenotype or non-biologically active or cannabidiol
phenotype.25The relative amounts in cannabis vapor extract give a drug
phenotype or more precisely D9THC phenotype. Where the
phenotype ratio of cannabis extract = THC% content/
CBD%= 67.9%/32.1%> 1.
The investigation of the therapeutic effects of cannabinoids
on some cancer-related disorders has provided evidence of
their effectiveness in the alleviation of several symptoms
observed in cancer patients, such as appetite loss and neuro-
pathic pain.26 Beyond the palliative effects induced by these
compounds, previous advances in the knowledge of the biolog-
ical role of endocannabinoids and novel insights into the
molecular signaling of cannabinoid receptors, support the par-
ticipation of the endocannabinoid system in the regulation of
key processes involved in the development of cancer.27,28 So
this study aimed to evaluate the possible protective and thera-
peutic effects of cannabis extract on DMNA-induced hepato-
carcinogenicity in mice.
In this study, there was a signiﬁcant increase in the expres-
sion of TERT mRNA in the DMNA group (group II) as com-
pared to the control group. The higher increase of TERT
mRNA level in the DMNA group was in parallel to that
reported by Braicu et al.29 and Miura et al.30 Although telome-
rase is not carcinogenic, it plays a direct role in oncogenesis by
allowing the precancerous cells to proliferate continuously and
Effects of cannabis plant extract on liver cancer 249become immortal. These results were conﬁrmed by the histo-
pathological ﬁndings in the control group, and DMNA group.
Telomerase has been found to be expressed in most immor-
tal cell lines, but it was undetectable in adult normal tissues, so
in malignant tumors telomerase is thought to be activated to
maintain their immortality. It has been suggested that telome-
rase is one of the critical steps in malignant transformation and
its strong enhancement considered an important part of
hepatocarcinogenesis.31
On the other hand, there was a signiﬁcant decrease in the
expression of TERT mRNA in groups III, IV, and V as com-
pared to group II. These results may be due to the protective
effect of the pretreatment and therapeutic effect of (simulta-
neous and post-treatment) cannabis extract. Vara et al.32 study
of cannabinoids on HCC showed that D9-THC and JWH-015
(synthetic cannabinoids) efﬁciently reduced ascites develop-
ment and alpha fetoprotein (AFP) expression in HCC,
which also paralleled mammalian target of rapamycin C1
(mTORC1) inhibition, adenosine monophosphate-activated
kinase (AMPK) activation and autophagy stimulation in those
tumors. Their data represent the ﬁrst evidence for the anti-pro-
liferative action of cannabinoids in HCC cells in vivo and sup-
port that the ability of cannabinoids to inhibit mTORC1,
stimulate AMPK and enhance autophagy could be therapeuti-
cally exploited for the management of HCC. In addition, the
ability of THC to reduce inﬂammation (a pro-tumorigenic
function of the immune system), and this effect may seem to
be beneﬁcial for preventing certain types of cancer.33
Our ﬁndings suggested that the treatment with cannabis
extract inhibits TERT mRNA expression level which leads
to down regulation of telomerase activity.
In the current work, TERT mRNA expression level in
groups III, VI and V showed insigniﬁcant change when com-
pared with each other. This insigniﬁcant difference may be
attributed to cannabinoid treatment, where cannabinoids
impair tumor progression at different levels through the
inhibition of cancer cell proliferation. These results are in line
with in vivo experiments which indicated that cannabinoids
impair tumor angiogenesis and block invasion and
metastasis.34
These results are conﬁrmed by the histopathological study
which revealed that the liver shows frequent apoptotic hepato-
cytes with condensed nuclei and wide areas of necrosis in
group III, spotty coagulative necrosis in group IV and coagu-
lative necrosis in group V.
In the present study, there was a signiﬁcant decrease in the
expression of caspase-8 mRNA in groups II, III, IV and V as
compared to the control group. The lower level of caspase-8
mRNA expression in the DMNA group was in agreement with
previous studies which found that caspase-8 is frequently
silenced by promoter hypermethylation indicating that tumor-
igenesis is associated with inactivation of caspase-8.35,36
Caspase-8 is a key signaling molecule of apoptosis, loss of
caspase-8 expression or function has a profound impact on
the cancer cell’s ability to undergo apoptosis. Various mecha-
nisms including genetic, epigenetic and posttranslational alter-
ations have been identiﬁed that cause inactivation of this
central apoptosis regulator in human cancers.11 Loss or dys-
function of caspase-8 results in increased cellular transforma-
tion, enhanced tumor progression, poor response to
chemotherapy, and impaired prognosis of patients of different
cancer entities.37,38On the other hand, there was a signiﬁcant increase in the
expression of caspase-8 mRNA in group III as compared to
the corresponding values in group II. Our results may be due
to the administration of cannabis plant extract as a protective
treatment. These results were in agreement with a previous
study of Lombard and his associates39 which showed that
THC treatment of the cells led to the activation of caspases
2, 8, 9, and 10 in that order, and cleavage of Bid occurred
2 h after treatment. Overall, these studies demonstrated that
THC-induced apoptosis was occurring through cross-talk
between the extrinsic and intrinsic pathways, with the intrinsic
pathway playing the primary role. Also, Giuliano et al.40
found that modulation of both cannabinoid receptors by some
synthetic cannabinoids induces apoptosis in a hepatocellular
carcinoma cell line.
The most prevalent effect of cannabinoids is the induction
of cancer cell death by apoptosis and the inhibition of cancer
cell proliferation. At least one of these actions has been dem-
onstrated in almost all the cancer cell types tested.34
This study revealed that, there was no signiﬁcant change in
caspase-8 mRNA expression level in groups IV and V as com-
pared to group II as well as in group IV as compared to group
III, while it was signiﬁcantly decreased in group V as com-
pared to group III. These results may be due to that, the per-
centage of apoptotic cells after treatment was increased both in
a time-dependent manner and in a dose-dependent manner.41
Our study demonstrated that there was a signiﬁcant
decrease in the hepatic activities of both ALT and AST in
groups II, III, IV, and V as compared to the control group.
DMNA induces liver ﬁbrosis in a highly reproducible manner,
ﬁrst inducing a central hemorrhagic necrosis followed by the
formation of septa and establishing micronodular cirrhosis
after 3 weeks of treatment.42 Lower hepatic AST and ALT
activities might be attributed to the damage of the liver tissue
due to the alteration of the membrane components in the tis-
sue, resulting in the release of these enzymes into the blood.43
We suggested that the decrease in the hepatic activities of AST
and ALT in our results has been positively correlated with the
increased liver damage.
The hepatic activities of ALT and AST were signiﬁcantly
increased in groups III, IV, and V as compared to group II,
but still signiﬁcantly decreased as compared to the control
group. This partial improvement in the enzyme activities
may be due to the protective effect of the pretreatment and
therapeutic effect of (simultaneous and post-treatment) canna-
bis extract, in addition to non toxicity of the cannabis extracts
in the liver tissue.13 Also, cannabidiol pretreatment signiﬁ-
cantly attenuated the elevations of serum aminotransferases,
decreased oxidative and nitrative stress, and reduced the
inﬂammatory response in the liver tissue. The antioxidant,
anti-inﬂammatory and antiapoptotic activities can be consid-
ered the main factors responsible for the hepatoprotective
effect of cannabidiol. Therefore, cannabidiol may be a feasible
therapeutic candidate to prevent liver tissue injury.44
In the present study there was a signiﬁcant increase in the
hepatic activity of c-GT in groups II, III, IV, and V as com-
pared to the control group. These results are in agreement with
a previous study.45 The elevated values of c-GT activity in
their study are an indication of parenchymal cell damage
and induction of hepatic necrosis and premalignant hepatocel-
lular damage induced by DMNA administration. c-GT is the
most sensitive indicator of hepatobiliary disease.46
250 N.A.E.M. Hussein et al.The activities of c-GT are rather low in normal liver tissues,
expressed mainly on the border of epithelial cell membrane of
biliary duct and intrahepatic cholangioles with strong secre-
tory and absorptive functions. With the feature of carcinoem-
bryonic protein, hepatoma-related c-GT is produced and
secreted when the genes controlling c-GT synthesis were
expressed abnormally. Hence c-GT is usually considered as
the early enzyme marker of hepatocarcinogenesis.47 These
results were conﬁrmed by the histopathological study which
revealed that the liver showed well differentiated HCC with
foci of necrosis in group II.
On the other hand, there was a signiﬁcant decrease in c-GT
activity in groups III, IV, and V as compared to group II.
These results may be due to the protective and therapeutic
effects of cannabis extract. Numerous studies show that
THC and other cannabinoids exhibit anti-tumor effects on a
wide range of animal models of cancer.13,48 Administration
of cannabinoids to tumor-bearing mice decreased the activity
and expression of matrix metalloproteinase-2 (a proteolytic
enzyme that allows tissue breakdown and remodeling during
angiogenesis and metastasis).49
The obtained results were conﬁrmed by the correlation
study, which indicated that there was a signiﬁcant positive cor-
relation between ALT, AST activities and caspase-8 gene
expression and also between c-GT activity and TERT gene
expression. In addition the signiﬁcant negative correlation
between c-GT activity and each of ALT, AST activities, cas-
pase-8 gene expression and also between TERT gene expres-
sion and the activities of both ALT and AST. These results
may be due to that hepatic injury, cellular leakage and loss
of the functional integrity of the liver cell membrane induced
by DMNA lead to decreasing levels of ALT, AST activities,
and caspase-8 gene and increasing levels of both TERT gene
expression and c-GT activity.
In conclusion, exposure to DMNA plays a role in patho-
genesis of liver disease leading to carcinogenicity and causes
disturbances in the activities of mice liver enzymes while
cannabis causes a partial improvement in these enzymes. The
protective effect of cannabis extract is more pronounced
than other groups and this is demonstrated in group III. Can-
nabinoids might exert their anti-tumor effects by direct induc-
tion of apoptosis and can decrease telomerase activity by
inhibiting the expression of hTERT gene. Coordination
between inhibition of telomerase activity and induction of
apoptosis might be a potential therapeutic agent for cancer
treatment.
It is widely believed that strategies that aim to reduce mor-
tality from cancer should consist of targeted therapies that are
capable of providing the most efﬁcacious and selective treat-
ment for each individual tumor and patient.
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